{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T03:51:21Z","timestamp":1774151481829,"version":"3.50.1"},"reference-count":109,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/SAU-SER\/30388\/2017"],"award-info":[{"award-number":["PTDC\/SAU-SER\/30388\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04378\/2020 and UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020 and UIDB\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Prostate cancer (PCa) is the second most diagnosed cancer in men worldwide. For its screening, serum prostate specific antigen (PSA) test has been largely performed over the past decade, despite its lack of accuracy and inability to distinguish indolent from aggressive disease. Metabolomics has been widely applied in cancer biomarker discovery due to the well-known metabolic reprogramming characteristic of cancer cells. Most of the metabolomic studies have reported alterations in urine of PCa patients due its noninvasive collection, but the analysis of prostate tissue metabolome is an ideal approach to disclose specific modifications in PCa development. This review aims to summarize and discuss the most recent findings from tissue and urine metabolomic studies applied to PCa biomarker discovery. Eighteen metabolites were found consistently altered in PCa tissue among different studies, including alanine, arginine, uracil, glutamate, fumarate, and citrate. Urine metabolomic studies also showed consistency in the dysregulation of 15 metabolites and, interestingly, alterations in the levels of valine, taurine, leucine and citrate were found in common between urine and tissue studies. These findings unveil that the impact of PCa development in human metabolome may offer a promising strategy to find novel biomarkers for PCa diagnosis.<\/jats:p>","DOI":"10.3390\/metabo11030181","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T23:47:41Z","timestamp":1616370461000},"page":"181","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1439-770X","authenticated-orcid":false,"given":"Ana Rita","family":"Lima","sequence":"first","affiliation":[{"name":"UCIBIO\/REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-8364","authenticated-orcid":false,"given":"Joana","family":"Pinto","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"given":"Filipa","family":"Amaro","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"given":"Maria de Lourdes","family":"Bastos","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-4751","authenticated-orcid":false,"given":"M\u00e1rcia","family":"Carvalho","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"},{"name":"UFP Energy, Environment and Health Research Unit (FP-ENAS), University Fernando Pessoa, Pra\u00e7a Nove de Abril, 349, 4249-004 Porto, Portugal"},{"name":"Faculty of Health Sciences, University Fernando Pessoa, Rua Carlos da Maia, 296, 4200-150 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7395-5700","authenticated-orcid":false,"given":"Paula","family":"Guedes de Pinho","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-319-95693-0_2","article-title":"Novel Biomarkers for Prostate Cancer Detection and Prognosis","volume":"1095","author":"Filella","year":"2018","journal-title":"Adv. Exp. Med. Biol"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"12620","DOI":"10.3390\/ijms140612620","article-title":"The present and future of prostate cancer urine biomarkers","volume":"14","author":"Rigau","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3322\/caac.20066","article-title":"American Cancer Society guideline for the early detection of prostate cancer: Update 2010","volume":"60","author":"Wolf","year":"2010","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MOU.0000000000000510","article-title":"Prostate biopsy: Guidelines and evidence","volume":"28","author":"Hubner","year":"2018","journal-title":"Curr. Opin. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41391-019-0127-4","article-title":"Approaches to urinary detection of prostate cancer","volume":"22","author":"Eskra","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/annonc\/mdu525","article-title":"Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis","volume":"26","author":"Louie","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11934-018-0828-6","article-title":"Improving the Specificity of PSA Screening with Serum and Urine Markers","volume":"19","author":"Kearns","year":"2018","journal-title":"Curr. Urol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.crad.2019.03.016","article-title":"Prostate biopsy: When and how to perform","volume":"74","author":"Das","year":"2019","journal-title":"Clin. Radiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1590\/s1677-5538.ibju.2016.0656","article-title":"Biochemical recurrence after radical prostatectomy: What does it mean?","volume":"44","author":"Srougi","year":"2018","journal-title":"Int. Braz. J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11864-017-0462-4","article-title":"Management Options for Biochemically Recurrent Prostate Cancer","volume":"18","author":"Fakhrejahani","year":"2017","journal-title":"Curr. Treat Options Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of Advanced Prostate Cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Ann. Rev. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/iju.13326","article-title":"Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice","volume":"24","author":"Narayan","year":"2017","journal-title":"Int. J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.3346\/jkms.2018.33.e94","article-title":"Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study","volume":"33","author":"Park","year":"2018","journal-title":"J. Korean Med. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CCO.0000000000000065","article-title":"Biomarkers in prostate cancer: What\u2019s new?","volume":"26","author":"Sartori","year":"2014","journal-title":"Curr. Opin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semcancer.2018.01.012","article-title":"New biomarkers for diagnosis and prognosis of localized prostate cancer","volume":"52","author":"Chistiakov","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1586\/14737159.2015.1011622","article-title":"Commercialized biomarkers: New horizons in prostate cancer diagnostics","volume":"15","author":"Murphy","year":"2015","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.tranon.2016.05.004","article-title":"Biomarker Discovery in Human Prostate Cancer: An Update in Metabolomics Studies","volume":"9","author":"Lima","year":"2016","journal-title":"Transl. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/004982599238047","article-title":"\u2018Metabonomics\u2019: Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data","volume":"29","author":"Nicholson","year":"1999","journal-title":"Xenobiotica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jpba.2014.12.017","article-title":"Metabolomics for laboratory diagnostics","volume":"113","author":"Bujak","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2013.08.041","article-title":"Metabolomics in cancer biomarker discovery: Current trends and future perspectives","volume":"87","author":"Armitage","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Marchand, C.R., Farshidfar, F., Rattner, J., and Bathe, O.F. (2018). A Framework for Development of Useful Metabolomic Biomarkers and Their Effective Knowledge Translation. Metabolites, 8.","DOI":"10.3390\/metabo8040059"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/14737159.2018.1481391","article-title":"A review of validated biomarkers obtained through metabolomics","volume":"18","author":"Barbas","year":"2018","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.bbabio.2011.03.006","article-title":"Metabolomics for mitochondrial and cancer studies","volume":"1807","author":"Nagrath","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/2213235X113019990005","article-title":"Biomarker Discovery and Translation in Metabolomics","volume":"1","author":"Raftery","year":"2013","journal-title":"Curr. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22335","DOI":"10.1039\/C8RA01574K","article-title":"Advances in mass spectrometry-based metabolomics for investigation of metabolites","volume":"8","author":"Ren","year":"2018","journal-title":"RSC Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnmrs.2017.01.001","article-title":"Beyond the paradigm: Combining mass spectrometry and nuclear magnetic resonance for metabolomics","volume":"100","author":"Marshall","year":"2017","journal-title":"Prog. Nucl. Magn. Reason. Spectrosc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.4155\/bio-2019-0014","article-title":"Analytical techniques for metabolomic studies: A review","volume":"11","author":"Segers","year":"2019","journal-title":"Bioanalysis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mas.20108","article-title":"Mass spectrometry-based metabolomics","volume":"26","author":"Dettmer","year":"2007","journal-title":"Mass. Spectrom. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.4155\/bio.09.158","article-title":"Mass spectrometry-based technologies for high-throughput metabolomics","volume":"1","author":"Han","year":"2009","journal-title":"Bioanalysis"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Crook, A.A., and Powers, R. (2020). Quantitative NMR-Based Biomedical Metabolomics: Current Status and Applications. Molecules, 25.","DOI":"10.3390\/molecules25215128"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.anchem.1.031207.113026","article-title":"Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics","volume":"1","author":"Lindon","year":"2008","journal-title":"Ann. Rev. Anal. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trac.2011.08.009","article-title":"Metabolite identification and quantitation in LC-MS\/MS-based metabolomics","volume":"32","author":"Xiao","year":"2012","journal-title":"Trends Anal. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11306-018-1384-2","article-title":"NMR-based metabolomics studies of human prostate cancer tissue","volume":"14","author":"Lima","year":"2018","journal-title":"Metabolomics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3390\/metabo3030787","article-title":"A comprehensive workflow of mass spectrometry-based untargeted metabolomics in cancer metabolic biomarker discovery using human plasma and urine","volume":"3","author":"Zou","year":"2013","journal-title":"Metabolites"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pnmrs.2016.01.005","article-title":"Applications of NMR spectroscopy to systems biochemistry","volume":"92","author":"Fan","year":"2016","journal-title":"Prog. Nucl. Magn. Reason. Spectrosc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jaci.2017.04.021","article-title":"A review of metabolomics approaches and their application in identifying causal pathways of childhood asthma","volume":"141","author":"Turi","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-3-319-47656-8_9","article-title":"Applications of Metabolomics in Cancer Studies","volume":"965","author":"Armitage","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"bpz014","DOI":"10.1093\/biomethods\/bpz014","article-title":"Digging deeper into volatile organic compounds associated with cancer","volume":"4","author":"Janfaza","year":"2019","journal-title":"Biol. Methods Protoc."},{"key":"ref_40","first-page":"232","article-title":"Urinary metabolites for urological cancer detection: A review on the application of volatile organic compounds for cancers","volume":"7","author":"Gao","year":"2019","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jpba.2017.07.013","article-title":"GC-MS based metabolomics used for the identification of cancer volatile organic compounds as biomarkers","volume":"147","author":"Lubes","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2010.10.006","article-title":"Olfactory detection of prostate cancer by dogs sniffing urine: A step forward in early diagnosis","volume":"59","author":"Cornu","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.juro.2014.09.099","article-title":"Olfactory system of highly trained dogs detects prostate cancer in urine samples","volume":"193","author":"Taverna","year":"2015","journal-title":"J. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jveb.2017.03.004","article-title":"Olfactory detection of cancer by trained sniffer dogs: A systematic review of the literature","volume":"19","author":"Pirrone","year":"2017","journal-title":"J. Vet. Behav."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Perrotti, F., Rosa, C., Cicalini, I., Sacchetta, P., Del Boccio, P., Genovesi, D., and Pieragostino, D. (2016). Advances in Lipidomics for Cancer Biomarkers Discovery. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17121992"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-319-77736-8_3","article-title":"The Heterogeneity of Lipid Metabolism in Cancer","volume":"1063","author":"Park","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.tibs.2016.08.010","article-title":"Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences","volume":"41","author":"Yang","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.copbio.2016.11.008","article-title":"Recent advances in expanding the coverage of the lipidome","volume":"43","author":"Tumanov","year":"2017","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-4939-9027-6_11","article-title":"Lipidomic Analysis of Cancer Cell and Tumor Tissues","volume":"1928","author":"Islam","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12272-015-0552-4","article-title":"Cancer metabolomics in basic science perspective","volume":"38","author":"Kwon","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fonc.2017.00131","article-title":"The Metabolic Phenotype of Prostate Cancer","volume":"7","author":"Eidelman","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coemr.2020.02.003","article-title":"Metabolic alterations in tissues and biofluids of patients with prostate cancer","volume":"10","author":"Andersen","year":"2020","journal-title":"Curr. Opin. Endocr. Metab. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"a030569","DOI":"10.1101\/cshperspect.a030569","article-title":"Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities","volume":"8","author":"Zadra","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.tem.2015.07.001","article-title":"Metabolomic profiling of hormone-dependent cancers: A bird\u2019s eye view","volume":"26","author":"Lloyd","year":"2015","journal-title":"Trends Endocr. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/bst0310375","article-title":"Polyamines and prostatic cancer","volume":"31","author":"Schipper","year":"2003","journal-title":"Biochem. Soc. Trans."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"a030452","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen Signaling in Prostate Cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nature07762","article-title":"Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression","volume":"457","author":"Sreekumar","year":"2009","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00216-011-5098-9","article-title":"GC\/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization","volume":"401","author":"Wu","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.juro.2010.09.077","article-title":"Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression","volume":"185","author":"Jentzmik","year":"2011","journal-title":"J. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.eururo.2010.01.035","article-title":"Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours; Discussion 20-1","volume":"58","author":"Jentzmik","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/pros.22706","article-title":"TMEFF2 and SARDH cooperate to modulate one-carbon metabolism and invasion of prostate cancer cells","volume":"73","author":"Green","year":"2013","journal-title":"Prostate"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/138955710793564106","article-title":"Vitamin Bs, one carbon metabolism and prostate cancer","volume":"10","author":"Donkena","year":"2010","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/pros.23088","article-title":"Decreased expression of lysophosphatidylcholine (16:0\/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer","volume":"75","author":"Goto","year":"2015","journal-title":"Prostate"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"32272","DOI":"10.1038\/srep32272","article-title":"Metabolite Analysis and Histology on the Exact Same Tissue: Comprehensive Metabolomic Profiling and Metabolic Classification Prostate Cancer","volume":"6","author":"Huan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"20984","DOI":"10.1038\/srep20984","article-title":"Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1074\/mcp.M115.052381","article-title":"Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer","volume":"15","author":"Ren","year":"2016","journal-title":"Mol. Cell. Proteom."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"42071","DOI":"10.18632\/oncotarget.9817","article-title":"Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer","volume":"7","author":"Hansen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11306-016-1055-0","article-title":"Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy","volume":"12","author":"Madhu","year":"2016","journal-title":"Metabolomics"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/bjc.2017.346","article-title":"Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy","volume":"117","author":"Braadland","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ijc.31313","article-title":"Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer","volume":"143","author":"Shao","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1038\/s41598-018-23177-w","article-title":"Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue","volume":"8","author":"Vandergrift","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12944-019-1130-4","article-title":"Racial differences in distribution of fatty acids in prostate cancer and benign prostatic tissues","volume":"18","author":"Zhou","year":"2019","journal-title":"Lipids Health Dis."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Franko, A., Shao, Y., Heni, M., Hennenlotter, J., Hoene, M., Hu, C., Liu, X., Zhao, X., Wang, Q., and Birkenfeld, A.L. (2020). Human Prostate Cancer is Characterized by an Increase in Urea Cycle Metabolites. Cancers, 12.","DOI":"10.3390\/cancers12071814"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cca.2019.10.046","article-title":"NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer","volume":"501","author":"Zheng","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Dudka, I., Thysell, E., Lundquist, K., Antti, H., Iglesias-Gato, D., Flores-Morales, A., Bergh, A., Wikstrom, P., and Grobner, G. (2020). Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06908-z"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1158\/1078-0432.CCR-11-2929","article-title":"Changes in Gene Transcription Underlying the Aberrant Citrate and Choline Metabolism in Human Prostate Cancer Samples","volume":"18","author":"Bertilsson","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/ddi227","article-title":"Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations","volume":"14","author":"Pollard","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1172\/JCI67228","article-title":"Oncometabolites: Linking altered metabolism with cancer","volume":"123","author":"Yang","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1038\/sj.onc.1209594","article-title":"Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer","volume":"25","author":"King","year":"2006","journal-title":"Oncogene"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.juro.2014.10.085","article-title":"HIF1alpha expression under normoxia in prostate cancer--which pathways to target?","volume":"193","author":"Ranasinghe","year":"2015","journal-title":"J. Urol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Staal, J., and Beyaert, R. (2018). Inflammation and NF-kappaB Signaling in Prostate Cancer: Mechanisms and Clinical Implications. Cells, 7.","DOI":"10.3390\/cells7090122"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.molmet.2020.02.005","article-title":"A non-proliferative role of pyrimidine metabolism in cancer","volume":"35","author":"Siddiqui","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2005.07.003","article-title":"Pyrimidine pathways in health and disease","volume":"11","author":"Loffler","year":"2005","journal-title":"Trends Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jgg.2015.04.004","article-title":"Pyrimidine Metabolism: Dynamic and Versatile Pathways in Pathogens and Cellular Development","volume":"42","author":"Garavito","year":"2015","journal-title":"J. Genet. Genom."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3892\/ijo.2017.3885","article-title":"The one-carbon metabolism pathway highlights therapeutic targets for gastrointestinal cancer (Review)","volume":"50","author":"Konno","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cmet.2020.06.019","article-title":"Mitochondrial Metabolism as a Target for Cancer Therapy","volume":"32","author":"Vasan","year":"2020","journal-title":"Cell Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yexmp.2011.11.001","article-title":"The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer","volume":"92","author":"Zhou","year":"2012","journal-title":"Exp. Mol. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Gomez-Cebrian, N., Rojas-Benedicto, A., Albors-Vaquer, A., Lopez-Guerrero, J.A., Pineda-Lucena, A., and Puchades-Carrasco, L. (2019). Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers. Metabolites, 9.","DOI":"10.3390\/metabo9030048"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"981458","DOI":"10.1155\/2015\/981458","article-title":"Current Challenges in Volatile Organic Compounds Analysis as Potential Biomarkers of Cancer","volume":"2015","author":"Schmidt","year":"2015","journal-title":"J. Biomark."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ajcn\/84.3.531","article-title":"Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans","volume":"84","author":"Walsh","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jpba.2014.12.026","article-title":"Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study","volume":"111","author":"Kordalewska","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Khalid, T., Aggio, R., White, P., De Lacy Costello, B., Persad, R., Al-Kateb, H., Jones, P., Probert, C.S., and Ratcliffe, N. (2015). Urinary Volatile Organic Compounds for the Detection of Prostate Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143283"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Tsoi, T.H., Chan, C.F., Chan, W.L., Chiu, K.F., Wong, W.T., Ng, C.F., and Wong, K.L. (2016). Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162217"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"38243","DOI":"10.1038\/srep38243","article-title":"Prostate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics","volume":"6","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/ijms.15783","article-title":"Amino Acid Profiles of Serum and Urine in Search for Prostate Cancer Biomarkers: A Pilot Study","volume":"14","author":"Derezinski","year":"2017","journal-title":"Int. J. Med. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11306-017-1194-y","article-title":"Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia","volume":"13","year":"2017","journal-title":"Metabolomics"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"243.e21","DOI":"10.1016\/j.urolonc.2017.12.026","article-title":"Furan and p-xylene as candidate biomarkers for prostate cancer","volume":"36","author":"Iribar","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41416-019-0585-4","article-title":"Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine","volume":"121","author":"Lima","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2174\/0929867324666171006150326","article-title":"Metabolomic Heterogeneity of Urogenital Tract Cancers Analyzed by Complementary Chromatographic Techniques Coupled with Mass Spectrometry","volume":"26","author":"Arlette","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Amante, E., Salomone, A., Alladio, E., Vincenti, M., Porpiglia, F., and Bro, R. (2019). Untargeted Metabolomic Profile for the Detection of Prostate Carcinoma-Preliminary Results from PARAFAC2 and PLS-DA Models. Molecules, 24.","DOI":"10.3390\/molecules24173063"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11306-020-01691-1","article-title":"New findings on urinary prostate cancer metabolome through combined GC-MS and (1)H NMR analytical platforms","volume":"16","author":"Lima","year":"2020","journal-title":"Metabolomics"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Lima, A.R., Pinto, J., Carvalho-Maia, C., Jeronimo, C., Henrique, R., Bastos, M.L., Carvalho, M., and Guedes de Pinho, P. (2020). A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers. Cancers, 12.","DOI":"10.3390\/cancers12082017"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/mrm.10614","article-title":"Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI\/3D-MRSI-targeted postsurgical prostate tissues","volume":"50","author":"Swanson","year":"2003","journal-title":"Magn. Reason. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mrm.21647","article-title":"Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using 1H HR-MAS total correlation spectroscopy","volume":"60","author":"Swanson","year":"2008","journal-title":"Magn. Reason. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1021\/pr4004135","article-title":"HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease","volume":"12","author":"Tripathi","year":"2013","journal-title":"J. Proteome Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s11306-014-0746-7","article-title":"Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: A review","volume":"11","author":"Emwas","year":"2015","journal-title":"Metabolomics"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"170138","DOI":"10.1038\/sdata.2017.138","article-title":"A decade after the metabolomics standards initiative it\u2019s time for a revision","volume":"4","author":"Spicer","year":"2017","journal-title":"Sci. Data"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1021\/acscentsci.8b00296","article-title":"In Vitro Tracking of Intracellular Metabolism-Derived Cancer Volatiles via Isotope Labeling","volume":"4","author":"Lee","year":"2018","journal-title":"ACS Cent. Sci."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/11\/3\/181\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:38:23Z","timestamp":1760161103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/11\/3\/181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":109,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["metabo11030181"],"URL":"https:\/\/doi.org\/10.3390\/metabo11030181","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]}}}